Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeted and Non-targeted Proteomics Data of Human Plasma Extracellular Vesicles in Colorectal Cancer and Healthy Volunteers

ABSTRACT: Targeted proteomics data was acquired from plasma extracellular vesicles; two pooled colorectal cancer group and two pooled healthy volunteers group. Non-targeted protemics data (selected reaction monitoring: SRM) was acquired from plasma extracellular vesicles; 209 colorectal cancer patients and 109 healthy volunteers.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Keiko Kasahara

PROVIDER: PXD018228 | JPOST Repository | Sat Mar 27 00:00:00 GMT 2021

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	181018_470_Fr1_1.raw	Raw
	181018_470_Fr1_2.raw	Raw
	181018_496_Fr1_1.raw	Raw
	181018_496_Fr1_2.raw	Raw
	181018_514_Fr1_1.raw	Raw

Items per page:

1 - 5 of 20

Similar Datasets

Extracellular vesicle membrane protein profiling and targeted mass spectrometry unveil novel plasma biomarkers for detection of colorectal cancer

Project description:Extracellular vesicles (EVs) are valuable sources for the discovery of useful cancer biomarkers. This study explores the potential usefulness of tumor cell-derived EV membrane proteins as plasma biomarkers for early detection of colorectal cancer (CRC). EVs were isolated from the culture supernatants of four CRC cell lines by ultracentrifugation, and their protein profiles were analyzed by LC-MS/MS. Bioinformatics analysis of identified proteins revealed 518 EV membrane proteins in common among at least three CRC cell lines. We next used accurate in-clusion mass screening (AIMS) in parallel with iTRAQ-based quantitative proteomic analysis to highlight candidate proteins and validated their presence in pooled plasma-generated EVs from 30 healthy controls and 30 CRC patients. From these, we chose 14 potential EV-derived targets for further quantification by targeted MS assay in a separate individual cohort comprising of 73 CRC and 80 healthy subjects. Quantitative analyses revealed significant increases in ADAM10, CD59 and TSPAN9 levels (2.19- to 5.26-fold, p <0.0001) in plasma EVs from CRC patients, with AUC values of 0.83, 0.95 and 0.87, respectively. Higher EV CD59 levels were significantly corre-lated with distant metastasis (p = 0.0475), and higher EV TSPAN9 levels were significantly asso-ciated with lymph node metastasis (p = 0.0011), distant metastasis at diagnosis (p = 0.0104) and higher TNM stage (p = 0.0065). A two-marker panel consisting of CD59 and TSPAN9 outper-formed the conventional marker CEA in discriminating CRC and stage I/II CRC patients from healthy controls, with AUC values of 0.98 and 0.99, respectively. Our results identify EV mem-brane proteins in common among CRC cell lines and altered plasma EV protein profiles in CRC patients, and suggest plasma EV CD59 and TSPAN9 as a novel biomarker panel for detecting early-stage CRC.

2023-03-11 | PXD038871 | Pride

E-PROT-108

Project description:Tissue-exudative extracellular vesicles of colorectal cancer

2023-06-21 | E-PROT-108 | ExpressionAtlas

IMP1/IGF2BP1 enters extracellular vesicles in colorectal cancer

Project description:IMP1/IGF2BP1 enters extracellular vesicles in colorectal cancer

2022-09-30 | GSE198804 | GEO

Dual targeted extracellular vesicles regulating oncogenic genes in pancreatic cancer

Project description:Dual targeted extracellular vesicles regulating oncogenic genes in pancreatic cancer

| PRJNA925940 | ENA

Colorectal cancer diagnostic model utilizing metagenomic and metabolomic data of stool microbial extracellular vesicles

Project description:Metabolomics and metagenomics-combined study to diagnose colorectal cancer using gut-microbiome-secreted extracellular vesicles

2020-01-14 | ST001307 | MetabolomicsWorkbench

Enhancer remodeling promotes resistance to epigenetic-targeted therapy and engenders tumor cell vulnerabilities

Project description:Drug resistance is a major clinical challenge in achieving durable responses to targeted cancer therapeutics. Resistance mechanisms to new classes of epigenetic-targeted drugs entering the clinic remain largely unexplored. We used BET inhibition in MYCN-amplified neuroblastoma as a prototype to model innate and acquired resistance to chromatin remodeling inhibitors in cancer. Genome-scale, pooled lentiviral ORF and CRISPR knockout rescue screens nominated the PI3K pathway as a key signaling node that mediates resistance to BET inhibition.

2018-12-13 | GSE107706 | GEO

Dual targeted extracellular vesicles regulating oncogenic genes in pancreatic cancer [sRNAseq]

Project description:Dual targeted extracellular vesicles regulating oncogenic genes in pancreatic cancer [sRNAseq]

| PRJNA925924 | ENA

Whole transcriptome analysis of endothelial cells (HUVECs) after treatment with plasma-sEVs from polytrauma patients

Project description:To assess inflammation associated gene expression in endothelial cells mediated by small extracellular vesicles (sEVs), HUVECs were treated for 8hrs with plasma-Evs isolated from polytrauma patients 4 and 24hrs after trauma and healthy probands.

2021-04-17 | GSE172210 | GEO

IMP1/IGF2BP1 enters extracellular vesicles in colorectal cancer

Project description:IMP1/IGF2BP1 enters extracellular vesicles in colorectal cancer

| PRJNA816905 | ENA

Dual targeted extracellular vesicles regulating oncogenic genes in pancreatic cancer [Mouse Array]

Project description:Dual targeted extracellular vesicles regulating oncogenic genes in pancreatic cancer [Mouse Array]

| PRJNA925942 | ENA